BioSpace News Archive

The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States.

EMPhASIS Cohort 2 Interim Analysis Confirmed 30 mg Dose of IMU-838 as Most Appropriate for Planned Phase 3 Program in Relapsing-Remitting Multiple Sclerosis, Expected to Begin in the Second Half of 2021

First quarter 2021 revenues increased 38% to $2.53 billion versus first quarter 2020; revenues excluding REGEN-COVTM(1) increased 20%

Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, announced that its management team will be participating in the Bank of America Securities 2021 Health Care Conference on Wednesday, May 12, 2021 via webcast.

First-Time Data for KEYTRUDA® (pembrolizumab) in Early-Stage Kidney Cancer and for LYNPARZA® (olaparib) in Early-Stage Breast Cancer To Be Featured in ASCO Plenary Session

Yselty® for uterine fibroids: US New Drug Application submissionplanned in Q3:21; European marketing approval recommendation anticipated in Q4:21

ITM AG, a leading radiopharmaceutical company, announced the establishment of a Chinese subsidiary, ITM Precision Medical Co., Ltd., in Shanghai, China.

American CryoStem Corporation announced that it has signed a Letter of Intent with Advanced Regenerative Associates, LLC of Tinton Falls, NJ for the development of a cell-based wound covering treatment for non-healing wounds, skin ulcers, and limb ischemia associated with type II diabetes, burns, and other systemic conditions.

The assisted living market is predicted to display noteworthy growth in the years ahead driven by a number of factors.

High prevalence of cancer, coupled with the increasing demand for targeted therapy drugs will drive oncology small molecule drugs sales